WILMINGTON, DE / ACCESSWIRE / October 10, 2019 / Rigrodsky & Long, P.A.:
- Do you own shares of Ra Pharmaceuticals, Inc. (NASDAQ GS:RARX)?
- Did you purchase any of your shares prior to October 10, 2019?
- Do you think the proposed buyout is fair?
- Do you want to discuss your rights?
Rigrodsky & Long, P.A. announces that it is investigating potential legal claims against the board of directors of Ra Pharmaceuticals, Inc. ("Ra Pharma" or the "Company") (NASDAQ GS: RARX) regarding possible breaches of fiduciary duties and other violations of law related to the Company's entry into an agreement to be acquired by UCB S.A. ("UCB") in a transaction valued at approximately $2.1 billion. Under the terms of the agreement, shareholders of Ra Pharma will receive $48.00 in cash for each share of Ra Pharma they own.
If you own common stock of Ra Pharma and purchased any shares before October 10, 2019, if you would like to learn more about this investigation, or if you have any questions concerning this announcement or your rights or interests, please contact Seth D. Rigrodsky or Gina M. Serra toll-free at (888) 969-4242, by e-mail at [email protected], or at https://www.rigrodskylong.com/offices-contact.
Rigrodsky & Long, P.A., with offices in Delaware, New York, and California, has recovered hundreds of millions of dollars on behalf of investors and achieved substantial corporate governance reforms in numerous cases nationwide, including federal securities fraud actions, shareholder class actions, and shareholder derivative actions.
Attorney advertising. Prior results do not guarantee a similar outcome.
CONTACT: Rigrodsky & Long, P.A. Seth D. Rigrodsky Gina M. Serra (888) 969-4242 (302) 295-5310 Fax: (302) 654-7530 [email protected] http://www.rigrodskylong.com
SOURCE: Rigrodsky & Long, P.A.